Lisanti Capital Growth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lisanti Capital Growth’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-305,095	Closed	-$3.84M	–	126
2022 Q3	$3.84M	Buy	+305,095	New	+$3.93M	0.51%	80
2022 Q2	–	Sell	-662,644	Closed	-$10.8M	–	105
2022 Q1	$10.8M	Buy	+662,644	New	+$10.6M	1.21%	24
2021 Q4	–	Sell	-219,450	Closed	-$3.15M	–	119
2021 Q3	$3.15M	Sell	219,450 -122,735	-36%	-$1.94M	0.46%	84
2021 Q2	$5.41M	Sell	342,185 -130,335	-28%	-$1.77M	0.67%	66
2021 Q1	$4.81M	Buy	+472,520	New	+$4.87M	0.62%	71
2019 Q2	–	Sell	-221,565	Closed	-$1.8M	–	100
2019 Q1	$1.8M	Buy	+221,565	New	+$1.9M	0.64%	70

Other funds holding BCRX

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Lisanti Capital Growth's BCRX Position: Q4 2022 in Review

Lisanti Capital Growth sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 305,095 shares — an estimated $3.84M sold.

Lisanti Capital Growth first reported a position in BCRX in Q1 2019 and held it in 6 quarters. The position peaked at $10.8M in Q1 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

Lisanti Capital Growth reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Lisanti Capital Growth sold 305,095 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $3.84M.
Lisanti Capital Growth first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Lisanti Capital Growth's BioCryst Pharmaceuticals position peaked at $10.8M in Q1 2022.
230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on Lisanti Capital Growth's 13F filing for Q4 2022, filed 6 Feb 2023.